Abstract Details

Title Changes In Neuro-endovascular Procedural Volume During The Covid-19 Pandemic: An International Multicenter Study

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 003

Objective The effect of Coronavirus disease 2019 (COVID-19) pandemic on performance of neuro-endovascular procedures has not been quantified.

Background The effect of Coronavirus disease 2019 (COVID-19) pandemic on performance of neuro-endovascular procedures has not been quantified.

Design/Methods We performed an audit of performance of neuro-endovascular procedures at 18 institutions (7 countries) for two periods; January to April 2019 and 2020, to identify changes in various core procedures. We divided the region where the hospital was located based on the median value of total number of COVID-19 cases per 100,00 population-into high and low prevalent regions

Results Between 2019 and 2020, there was a reduction in number of cerebral angiograms (30.9% reduction), mechanical thrombectomy (8% reduction), carotid artery stent placement for symptomatic (22.7% reduction) and asymptomatic (43.4% reduction) stenoses, intracranial angioplasty and/or stent placement (45% reduction), and endovascular treatment of unruptured intracranial aneurysms (44.6% reduction) and ruptured (22.9% reduction) and unruptured brain arteriovenous malformations (66.4% reduction). There was an increase in treatment of ruptured intracranial aneurysms (10% increase) and other neuro-endovascular procedures (34.9% increase). There was no relationship between procedural volume change and intuitional location in high or low COVID-19 prevalent regions. The procedural volume reduction was mainly observed in March-April 2020.

Conclusions We provided an international multicenter view of changes in neuro-endovascular practices to better understand the gaps in provision of care and identify individual procedures which are susceptible to change.

Authors/Disclosures
Hamza I. Maqsood, MD (Dept of Neurology) PRESENTER	Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Michael G. Abraham, MD (The University of Kansas Health System)	Dr. Abraham has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stryker Neurovascular.
Camilo R. Gomez, MD, F�鶹��ýӳ�� (University of Missouri)	Dr. Gomez has nothing to disclose.
Farhan Siddiq, MD	Dr. Siddiq has nothing to disclose.
Muhammad F. Suri, MD (St Cloud Hospital)	Dr. Suri has nothing to disclose.
Camilo R. Gomez, MD, F�鶹��ýӳ�� (University of Missouri)	Dr. Gomez has nothing to disclose.
Muhammad F. Ishfaq, MD	Dr. Ishfaq has nothing to disclose.
Muhammad F. Ishfaq, MD	Dr. Ishfaq has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��